cefroxadine has been researched along with Kidney-Failure--Chronic* in 1 studies
1 other study(ies) available for cefroxadine and Kidney-Failure--Chronic
Article | Year |
---|---|
Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.
The pharmacokinetics of cefroxadine was studied in 17 patients with terminal renal impairment, 10 of whom were undergoing 5 h dialysis sessions. The antibiotic was administered as a single oral dose of 500 mg. Cefroxadine followed a single compartment open kinetic model. During the interdialysis period in patients with terminal renal impairment, an average Cmax of 26.59 micrograms/ml and a tmax of 3.65 h were reached, which are greater than in patients with normal renal function. The serum half-life was reduced from 23.55 h in the interdialysis periods to 3.40 h during the dialysis sessions. The average extraction coefficient was 0.249. It is recommended that a 500 mg dose cefroxadine should be administered at the end of each dialysis session if the interdialysis period is 48 h. Topics: Adolescent; Adult; Aged; Cephalosporins; Cephradine; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Renal Dialysis | 1983 |